Search results
Sep 6, 2024 · The third dose of either 2024–2025 Moderna vaccine or 2024–2025 Pfizer-BioNTech vaccine is administered at least 8 weeks after the second dose. People ages 6 months and older who are moderately or severely immunocompromised
- FAQs for The Interim Clinical Considerations
Moderna: 1 dose of 2024–2025 Moderna (0.25 mL/25 ug) 4–8...
- Appendices, References, and Previous Updates
Everyone ages 6 months and older vaccinated outside the...
- Interim Clinical Considerations for Use of Covid-19 Vaccines
Recommendations for the use of 2024–2025 Novavax COVID-19...
- Product Info by U.S. Vaccine
Immunization providers should provide a Vaccine Information...
- Vaccine Recipient Education
Many people have questions about the coronavirus disease...
- ACIP General Best Practice Guidelines for Immunization
Concurrent administration of antimicrobial agents and...
- ACIP Altered Immunocompetence Guidelines for Immunizations
The first three doses should be separated by 4 weeks and the...
- EUI
CDC issued initial Emergency Use Instructions (EUI) for the...
- Covid-19 Vaccine Data Systems
The Centers for Disease Control and Prevention (CDC) —...
- Provider Requirements and Support
CDC COVID-19 Vaccination Program Has Ended. With these FDA...
- FAQs for The Interim Clinical Considerations
3 days ago · Under the FDA’s plan, third shots of the Pfizer/BioNTech or Moderna vaccines will be given eight months after the second dose. The agency says it is also likely that people who received the one ...
4 days ago · Just days after its advisory committee meeting voted to approve a third dose of Pfizer and BioNTech's COVID-19 vaccine, the FDA has followed through and cleared the shot.
Aug 28, 2024 · Pfizer-BioNTech COVID-19 Vaccine is indicated for individuals 5 through 11 years of age (via a 10mcg / 0.3mL single-dose vial presentation) and for individuals 6 months through 4 years of age (via a 3mcg / 0.3mL multi-dose vial (3 doses per vial) presentation).
Sep 5, 2024 · In an open-label, non-randomized study among healthcare workers in Israel, an increased immune response, lower rate of infection and severe illness was observed after a fourth dose when compared to a third dose. 1 An analysis of the potential benefits of a booster dose, using the epidemiologic data in the U.S., demonstrated incremental benefits ...
Oct 25, 2023 · For certain people who are immunocompromised, the CDC recommends an additional primary series dose of an mRNA vaccine (Moderna or Pfizer) plus an updated booster is recommended.
Sep 13, 2024 · Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway.
